Get the Stockscreener App
24.01
8.74%
-2.30
After Hours:
23.30
-0.71
-2.96%
Instil Bio Inc stock is traded at $24.01, with a volume of 79,000.
It is down -8.74% in the last 24 hours and up +26.43% over the past month.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize FRα, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.
See More
Previous Close:
$26.31
Open:
$26.65
24h Volume:
79,000
Relative Volume:
0.68
Market Cap:
$163.70M
Revenue:
-
Net Income/Loss:
$-156.09M
P/E Ratio:
-1.0004
EPS:
-24
Net Cash Flow:
$-102.69M
1W Performance:
-0.50%
1M Performance:
+26.43%
6M Performance:
+94.41%
1Y Performance:
+105.21%
1-Day Range:
$23.80
$26.65
1-Week Range:
$22.01
$26.80
52-Week Range:
$9.62
$92.00
Instil Bio Inc Stock (TIL) Company Profile
Name
Instil Bio Inc
Sector
Industry
Phone
(972) 499-3350
Address
3963 MAPLE AVENUE, DALLAS
Compare TIL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TIL
Instil Bio Inc
|
24.01 | 163.70M | 0 | -156.09M | -102.69M | -24.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 113.67B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 74.97B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.50B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.95B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 29.63B | 3.30B | -501.07M | 1.03B | -2.1146 |
Instil Bio Inc Stock (TIL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-25 | Upgrade | Jefferies | Hold → Buy |
| Nov-04-24 | Initiated | JMP Securities | Mkt Perform |
| Apr-12-24 | Downgrade | Jefferies | Buy → Hold |
| Nov-01-22 | Downgrade | Cowen | Outperform → Market Perform |
| Nov-01-22 | Downgrade | Truist | Buy → Hold |
| Aug-13-21 | Initiated | Robert W. Baird | Outperform |
| Apr-13-21 | Initiated | Cowen | Outperform |
| Apr-13-21 | Initiated | Morgan Stanley | Equal-Weight |
| Apr-13-21 | Initiated | Truist | Buy |
View All
Instil Bio Inc Stock (TIL) Latest News
(TIL) Investment Report - Stock Traders Daily
What Makes Instil Bio (TIL) a New Buy Stock - MSN
Instil Bio Announces Clinical Progress in China for - GlobeNewswire
Instil Bio Announces Clinical Progress in China for IMM2510/SYN-2510, a Clinical-Stage PD-L1xVEGF Bispecific Antibody - Marketscreener.com
Instil Bio Advances Lung Cancer Treatment: First Patient Dosed in Phase 1b/2 Trial of Novel PD-L1xVEGF Therapy - StockTitan
(TIL) Technical Data - Stock Traders Daily
Instil Bio Stock Soars After Jefferies Upgrade On 'Early Mover' Cancer Drug Candidate: Retail Jubilant - MSN
Jefferies Upgrades Instil Bio (TIL) - MSN
Bullish Outlook On Instil Bio's Investigational Cancer Drug: Jefferies Sees Over 300% Stock Upside - Benzinga
How To Trade (TIL) - Stock Traders Daily
Instil Bio Secures Loan to Refinance Facility - MSN
Long Term Trading Analysis for (TIL) - Stock Traders Daily
Trend Tracker for (TIL) - Stock Traders Daily
Instil Bio’s Strategic Shift To SYN-2510: A Speculative ‘Buy’ Opportunity (NASDAQ:TIL) - Seeking Alpha
(TIL) Trading Report - Stock Traders Daily
Instil Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update - The Manila Times
Instil Bio Secures Global Rights to PD-L1xVEGF Drug, Reports $122.9M Cash Position | TIL Stock News - StockTitan
2 Stocks Up Over 700% in 2024 That Could Soar Even Further - AOL
JMP Securities initiates Instil Bio shares at Market Perform on public offering - Investing.com Australia
Instil Bio, Inc.'s (NASDAQ:TIL) stock price dropped 18% last week; private equity firms would not be happy - Simply Wall St
Up Over 600% in 2024, Can Summit Therapeutics Stock Keep Rising? - The Motley Fool
Analysis of Curative Ventures V LLC's Strategic Reduction in Instil Bio Inc - Yahoo Finance
(TIL) Long Term Investment Analysis - Stock Traders Daily
Baird maintains price target on Instil Bio stock, stays upbeat - Investing.com
5 Top NASDAQ Biotech Stocks of 2024 - Nasdaq
FDA Oncology Approvals Accelerate as Global Cancer Rates Set to Climb 77% - Baystreet.ca
Instil Bio Stock Skyrockets 641% in One Week: Here's Why - MSN
BOXER CAPITAL, LLC Acquires New Stake in Instil Bio Inc - GuruFocus.com
Perceptive Advisors LLC Acquires New Stake in Instil Bio Inc - GuruFocus.com
Baird sees Instil Bio stock upside on promising SYN-2510 clinical data - Investing.com
Fantastic Fest 2024: Clowns Rule at Texas’ No-Joke Genre Event Set to Debut ‘Terrifier 3,’ ‘V/H/S Beyond,’ and More - IndieWire
B. Riley Analysts Decrease Earnings Estimates for Inspired Entertainment, Inc. (NASDAQ:INSE) - Defense World
The time has not yet come to remove your chips from the table: Instil Bio Inc (TIL) - SETE News
Financial Metrics Unveiled: Instil Bio Inc (TIL)’s Key Ratios in the Spotlight - The Dwinnex
Instil Bio (TIL) Stock Rises In Extended Session On Major Strategy Reveal - Stocks Telegraph
Inspired Entertainment, Inc. to Post Q3 2024 Earnings of $0.22 Per Share, B. Riley Forecasts (NASDAQ:INSE) - Defense World
Ice Nine Kills to Release Official Song for Slasher Film Terrifier 3 - MetalSucks
Baird retains price target, outperform rating on Instil Bio shares By Investing.com - Investing.com Australia
Ice Nine Kills are releasing a new single for Terrifier 3 - Kerrang!
Ice Nine Kills’ Upcoming Single “A Work of Art” to Feature on "Terrifier 3" Soundtrack - Ghost Cult Magazine
Here's Why Everyone's Talking About Summit Therapeutics - MSN
This is why everyone is talking about Summit TherapeuticsTHE BHARAT EXPRESS NEWS - The Bharat Express News
Instil Bio stock target raised by H.C. Wainwright on cancer drug outlook - Investing.com
instilbiocorppres2024091.htm - SEC.gov
ICE NINE KILLS announce new 'TERRIFIER'-themed single and video starring SHAVO ODADJIAN - Revolver Magazine
Instil Bio Inc Stock (TIL) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.49%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):